BeiSuMei 倍苏美 (Avatrombopag) 20mg*10 Tablets | Chengdu Brilliant China | GLT

Generic Information: BeiSuMei (Avatrombopag) — Chengdu Brilliant, China

BeiSuMei (倍苏美) is the avatrombopag maleate tablet of Chengdu Brilliant Pharmaceutical Co., Ltd., a Chengdu-based manufacturer that has sat on China's national list of top-100 pharmaceutical companies for more than a decade. The pack on this page is the 20 mg film-coated tablet, ten per box, carrying national drug approval number 国药准字H20244142 — the number any pharmacy or hospital in China can verify against the NMPA registry. As a Category 4 generic that passed or was deemed to have passed consistency of quality and efficacy evaluation, it delivers the originator molecule under domestic manufacturing economics.

What Is BeiSuMei (Avatrombopag) Used For?

Two indications. First, raising platelet counts in adults with chronic liver disease who face an elective diagnostic procedure or operation — the pre-procedure bridge that prevents platelet transfusion. Second, treating chronic primary immune thrombocytopenia in adults whose prior steroid or immunoglobulin treatment fell short, to lift counts and cut bleeding. Brilliant's file is notable among domestic generics because regulators separately cleared its ITP use after the initial CLD approval, making BeiSuMei one of the small group of Chinese avatrombopag brands indicated for both populations rather than CLD alone.

How Does BeiSuMei (Avatrombopag) Work?

The active ingredient stimulates the thrombopoietin receptor — c-Mpl — on bone-marrow megakaryocyte precursors, nudging them to proliferate and mature into platelet-producing cells. It acts at the transmembrane portion of the receptor rather than the natural TPO binding site, so endogenous thrombopoietin and the drug reinforce each other instead of competing. The clinical consequences follow directly: counts respond within three to five days, and because the molecule is a small, non-peptide compound without metal-binding groups, meals and dairy do not interfere with absorption.

Indications of BeiSuMei (China Label)

The Chinese label reads: for adults with chronic liver disease related thrombocytopenia scheduled to undergo elective diagnostic procedures or surgery, and for adults with chronic primary immune thrombocytopenia who had an insufficient response to prior therapy. Physicians in China also encounter it in supportive-care contexts — for example, planning liver biopsy or HCC ablation in thrombocytopenic cirrhotics — always under specialist judgment. The label itself carries the standard caution that chronic liver disease patients should not take the drug merely to push counts toward normal.

Dosage and Administration

Take tablets once daily with food, swallowed whole. In the CLD setting the doctor first reads the platelet count: under 40×10⁹/L, the course is three tablets (60 mg) each day for five days; at 40 to under 50×10⁹/L, two tablets (40 mg) daily for five days — beginning ten to thirteen days ahead of the procedure, with the operation timed five to eight days after the last dose. In ITP the start is one tablet daily, adjustable within a ceiling of two tablets (40 mg) per day to keep counts at or above 50×10⁹/L, with blood monitoring through treatment. A missed dose is taken promptly with the next day's schedule unchanged.

Side Effects of BeiSuMei

Expect the class profile: fever, headache, stomach pain, nausea, fatigue and peripheral swelling lead the list in liver-disease patients; ITP patients more often mention headache, nosebleed, bruising, gum bleeding, joint pain and respiratory infections. The caution that matters most is thromboembolism — platelets pushed too high can clot, so treatment runs alongside platelet monitoring, and warning signs (painful swollen calf, sudden breathlessness, chest pain) demand urgent care. Hypersensitivity to any excipient rules the drug out.

Storage Instructions

Store the box below 25°C in a dry place, sealed in its original blister, protected from light; there is no need to refrigerate. Keep it out of children's sight and reach, and check the printed expiry before starting a course.

Why Choose BeiSuMei from GLT?

BeiSuMei suits buyers who want a Chinese nationally-procured generic with dual-indication labeling and big-manufacturer accountability: Brilliant runs vertically integrated production from intermediates to finished dosage forms and has cleared regulatory inspections for export markets. GLT supplies sealed mainland boxes with the H20244142 number intact and visible, provides batch photographs before dispatch, quotes this brand next to the originator and the Lao/Bangladesh alternatives so budgets decide on facts, and keeps a human on WhatsApp +86 15234153837 and at [email protected] for every question between quotation and delivery.

How to Order BeiSuMei (Avatrombopag)

Send the number of boxes and your delivery country to WhatsApp +86 15234153837 or [email protected]. GLT replies with a formal quotation, courier options and payment instructions — typically inside one working day — and dispatches sealed stock with export documentation on confirmation. Hospital and clinic buyers can request CoA copies and bulk scheduling.

FAQ

Who makes BeiSuMei? Chengdu Brilliant Pharmaceutical Co., Ltd. (成都倍特药业), known in English as Brilliant Pharmaceuticals — approval number H20244142 is theirs.

Does BeiSuMei cover ITP or only liver-disease thrombocytopenia? Both — regulators extended its label to adult chronic ITP after the original CLD approval, which not every domestic generic can claim.

Is a Chinese generic really equivalent to Doptelet? Its approval route required consistency evaluation against the originator reference, covering the same 20 mg strength and dissolution behavior.

How fast do platelets rise? The count usually starts climbing within three to five days of the first dose and peaks around ten to thirteen days — which is why the five-day course is timed against the surgery date.

Can it be combined with dairy or antacids? Yes — unlike eltrombopag, avatrombopag does not bind calcium, iron or magnesium, so normal meals and common co-medications do not block absorption.